Drug intelligence / Profile preview

RD-004

Development stage: Preclinical
Lead developer: MegaPro Biomedical
Modality: Nanoparticles → Drug Delivery Systems

Overview

RD-004 is an investigational drug candidate currently in the preclinical research and development stage at MegaPro Biomedical. It is being developed for applications within the Central Nervous System (CNS). Although specific details regarding its molecular target, mechanism of action, and precise indication are not yet publicly disclosed, the candidate likely leverages MegaPro's core expertise in functionalized iron oxide nanoparticle technology for either therapeutic delivery or diagnostic imaging within the brain or spinal cord. The project is part of the company's early-stage R&D pipeline.

Beyond the preview

Go deeper on RD-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RD-004.

Explore the full profile